Alvogen today announced the introduction of Vancomycin Hydrochloride Capsules, USP, an antibacterial indicated to treat infections that include C. difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus. 

Our playing field is the international generic industry. This is an industry with vast untapped potential, both geographically and technically, as generic pharmaceuticals become available in more markets and new difficult-to-make formulations are added to the generic portfolio. The industry is recession resistant by nature and is an answer to rising healthcare costs and ongoing need to improve the efficiency of healthcare systems around the world.